PR83473

WAIBLINGEN, Germany, Mar. 27, 2020 /PRNewswire=KYODO JBN/--

Test delivers reliable results at the point of care in less than 2.5 hours

- One of the world's first multiplex molecular diagnostic tests that can

identify COVID-19 and distinguish it from nine other respiratory infections

with similar symptoms, like influenza

- The test meets the requirements of the World Health Organization (WHO) and

was developed together with Randox Laboratories Ltd.

Bosch Healthcare Solutions is currently working on the development of a

COVID-19 rapid testing kit for the Vivalytic platform and will launch this in

April 2020. The Vivalytic VRI test (Viral Respiratory Tract Infections) checks

the patient's sample for the SARS CoV-2 virus, which can lead to COVID-19, as

well as nine other possible viral respiratory diseases. To prevent the

continued rapid spread of COVID-19, it is necessary to identify infectious

patients with and without symptoms. With the Vivalytic VRI test, physicians can

quickly and efficiently distinguish between different infections with very

similar symptoms, like influenza, and immediately begin the appropriate

treatment. The test delivers a reliable result based on WHO guidelines in less

than 2.5 hours at the point of care, i.e. in close proximity to where the

patient's sample was collected. This means a time-consuming logistics chain, in

which the samples have to be transported, is no longer necessary.

"Together with our partner Randox, we have adapted the manual COVID-19 test,

which has existed just a few weeks, to the new, fully automated Vivalytic

platform from Bosch," said Marc Meier, Managing Director of Bosch Healthcare

Solutions GmbH. "Thanks to the extensive expertise of both companies, we have

succeeded in developing an innovative test in a very short time, which can

contribute to curbing the global spread of the coronavirus."

The Vivalytic platform is so easy to use that it can be handled in any clinic

or medical practice without the need for laboratory personnel: The sample is

taken from the patient's nose or throat using a swab and placed in the

cartridge without any complex preparation. The Vivalytic analyser then fully

automatically processes the cartridge, which already contains all the reagents

required for the test. Since the system in each cartridge is isolated, the risk

of infection during handling is minimized.

Vivalytic is a universal platform for molecular diagnostics that can be used to

perform various fully automatic laboratory tests in a short time. The open

design of the platform makes it compatible with manual tests from various

suppliers. The range of available tests is expected to grow steadily, enabling

physicians to initiate successful therapies based on rapid diagnosis.

Photo: https://mma.prnewswire.com/media/1135729/Vivalytic_VRI_test.jpg

Photo: https://mma.prnewswire.com/media/1135730/Bosch_Vivalytic_VRI.jpg

Press contact:

Thomas Berroth

Marketing & Communication

Thomas.berroth2@de.bosch.com

+49-71181145599

www.bosch-vivalytic.com

Source: Bosch Healthcare Solutions GmbH